BridgeBio Pharma, Inc. — 2023 Q3 Form 10-Q Summary
Business context and reporting period
BridgeBio is a commercial-stage biopharmaceutical company developing medicines for genetically driven diseases and cancers through wholly owned and controlled subsidiaries. The unaudited report covers the three and nine months ended September 30, 2023, with comparisons to the corresponding 2022 periods.
The company reported more than 15 ongoing clinical trials across over 20 disease states and stated that it has not generated significant product-sales revenue. Operations remain primarily funded through equity offerings, convertible debt, term debt, licensing arrangements and asset sales.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $4.1 million | $0.3 million | $7.6 million | $75.8 million |
| Research and development | $125.1 million | $92.5 million | $325.5 million | $308.6 million |
| SG&A | $35.8 million | $31.2 million | $103.0 million | $111.3 million |
| Restructuring, impairment and related charges | $0.3 million | $5.0 million | $7.2 million | $36.1 million |
| Loss from operations | $(157.7) million | $(129.1) million | $(430.0) million | $(383.0) million |
| Net loss | $(179.5) million | $(140.2) million | $(482.9) million | $(344.1) million |
| Net loss attributable to BridgeBio common stockholders | $(177.0) million | $(137.3) million | $(475.1) million | $(343.6) million |
| Loss per share, basic and diluted | $(1.08) | $(0.93) | $(2.99) | $(2.34) |
Revenue in Q3 2023 primarily comprised clinical-supply revenue and $1.3 million of services revenue under the Navire-BMS agreement. The filing does not present a positive profitability or operating margin; operating losses remained substantial.
- Net cash used in operating activities was $402.9 million for the first nine months of 2023, compared with $326.3 million in the prior-year period.
- Net cash provided by investing activities was $54.1 million, principally from marketable-security maturities and sales of equity securities.
- Net cash provided by financing activities was $456.1 million, primarily from a $241.3 million private placement, $144.0 million from a follow-on offering and $65.0 million from an ATM offering.
- Cash, cash equivalents and restricted cash increased to $524.1 million at September 30, 2023, from $416.9 million at December 31, 2022.
- Cash and cash equivalents were $505.2 million; restricted cash was $16.7 million; and equity investments were $38.1 million at September 30, 2023.
- Debt consisted of approximately $736.4 million of net 2029 Notes, $542.9 million of net 2027 Notes and $441.7 million of net term loan debt, or approximately $1.7 billion in total debt net of discounts, issuance costs and accretion.
Material changes versus the prior comparable period
- Nine-month revenue declined $68.2 million, primarily because 2022 included substantial revenue recognized from the Navire-BMS licensing transaction.
- Research and development expense increased $16.9 million for the nine-month period and $32.6 million in Q3, driven by higher licensing fees, stock-based compensation, personnel costs and program-development spending.
- Nine-month SG&A declined $8.3 million due mainly to restructuring-related cost reductions, lower personnel and legal costs, partly offset by commercialization-readiness spending. Q3 SG&A increased $4.6 million.
- Nine-month net loss increased $138.8 million year over year. The 2022 period benefited from a $107.9 million net gain on the sale of a priority review voucher, which did not recur in 2023.
- Restructuring, impairment and related charges declined $28.9 million for the nine months, from $36.1 million to $7.2 million.
- BridgeBio issued 8.9 million shares in the follow-on offering, 2.2 million shares through the ATM program and 9.2 million shares in the September private placement. These transactions increased liquidity but diluted existing holders.
- QED and Helsinn continued close-out activities following termination of their collaboration. Helsinn permanently discontinued TRUSELTIQ sales and requested withdrawal of the related NDA in May 2023; associated clinical investigations were discontinued.
- BridgeBio deconsolidated PellePharm during Q1 2023 after losing primary-beneficiary status and recognized a $1.2 million loss.
Guidance, outlook, risks and unusual items
Management expects operating and net losses to continue for at least the next several years and does not provide specific revenue, earnings or product-launch guidance in the filing. Management stated that available cash, restricted cash and equity investments are expected to fund operations for at least the next 12 months from the filing date under current plans and forecasts.
- The company may require additional financing sooner if operating plans or forecasts change. Future equity, debt or partnership financing may be unavailable or available only on unfavorable terms.
- The secured term loan bears fixed interest at 9.0%, with up to 3.0% permitted as payment-in-kind interest until January 1, 2025. Principal is scheduled to mature in 2026, subject to applicable amortization and milestone provisions.
- The term loan contains covenants and mandatory-prepayment provisions tied to certain asset sales, licensing, royalty and monetization transactions. It is secured by substantially all assets of BridgeBio and specified guarantor subsidiaries.
- The 2027 Notes mature in March 2027 and the 2029 Notes mature in February 2029. Both are convertible senior unsecured obligations and may require cash repurchase following specified fundamental changes.
- Potential performance-based milestone compensation totaled $189.5 million at September 30, 2023, of which $10.8 million was accrued as probable.
- Key risks include clinical-trial failure or delays, regulatory approval and market acceptance, dependence on contract manufacturers and research organizations, intellectual-property disputes, supply-chain disruption, inflation, interest-rate and financial-services risks, and the need for additional capital.
- Publicly traded equity investments are marked to market and may create material gains or losses. The company recorded a $5.4 million net loss from such investments in Q3 2023 and a $3.0 million net loss for the nine-month period.
- The company reported no material legal proceedings and stated that disclosure controls and procedures were effective as of September 30, 2023.
Most important facts for investors to verify
- Whether cash resources remain sufficient relative to the approximately $403 million nine-month operating cash burn and the company’s substantial debt maturities.
- Progress, regulatory status and commercialization prospects for key programs, particularly acoramidis, low-dose infigratinib, BBP-418, encaleret, BBP-631 and the KRAS inhibitor portfolio.
- The timing and amount of potential milestone receipts, licensing revenue and royalty income, which remain uncertain and largely contingent on clinical, regulatory and commercial outcomes.
- The impact of future ATM sales, equity financings, stock-based compensation and potential conversion of the 2027 and 2029 Notes on dilution.
- Compliance with term-loan covenants and mandatory-prepayment requirements, including the effect of future licensing, asset-sale or monetization transactions.
- The extent of remaining Helsinn close-out costs, potential reimbursements and obligations related to infigratinib and the withdrawal of the TRUSELTIQ NDA.
- Whether restructuring savings and reduced SG&A can offset continued growth in research and development spending.